financetom
Business
financetom
/
Business
/
Dream Industrial REIT to Launch Normal Course Issuer Bid
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Dream Industrial REIT to Launch Normal Course Issuer Bid
Mar 6, 2025 5:09 AM

07:54 AM EST, 03/06/2025 (MT Newswires) -- Dream Industrial REIT (DIR-UN.TO) on Thursday got the green light from the TSX to launch a normal course issuer bid for 10% of its public float.

The bid will commence March 10 run until March 9, 2026.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Lafayette Acquisition Corp Files For IPO Of Up To $100 Mln -SEC Filing
BRIEF-Lafayette Acquisition Corp Files For IPO Of Up To $100 Mln -SEC Filing
Sep 5, 2025
Sept 5 (Reuters) - Lafayette Acquisition Corp: * LAFAYETTE ACQUISITION CORP FILES FOR IPO OF UP TO $100 MILLION - SEC FILING * LAFAYETTE ACQUISITION CORP: TO LIST UNITS ON THE NASDAQ STOCK MARKET LLC UNDER THE SYMBOL LAFAU * LAFAYETTE ACQUISITION CORP: EARLYBIRDCAPITAL, INC IS UNDERWRITER TO IPO - SEC FILING Source text: ;)) ...
US clothing retailers test full-price strategy as rich shoppers keep spending
US clothing retailers test full-price strategy as rich shoppers keep spending
Sep 5, 2025
NEW YORK (Reuters) -A handful of apparel retailers including Levi's and Aritzia are teasing more full-priced products, testing how much wealthier shoppers are willing to pay despite the sobering effect of tariffs. They have not been disappointed so far. Levi Strauss, for instance, raised prices on some products in July but saw no slowdown in demand, the denim maker's chief financial...
BioNTech's Breast Cancer Drug Meets Primary Endpoint in Phase 3 Interim Analysis
BioNTech's Breast Cancer Drug Meets Primary Endpoint in Phase 3 Interim Analysis
Sep 5, 2025
06:01 AM EDT, 09/05/2025 (MT Newswires) -- BioNTech (BNTX) and China's Duality Biologics said Friday that their phase 3 trial evaluating trastuzumab pamirtecan in patients with a certain type of breast cancer met its primary endpoint in an interim analysis. A joint statement said the study, which compared BioNTech's trastuzumab pamirtecan drug candidate with Roche's approved antibody drug-conjugate trastuzumab emtansine,...
Vizsla Silver Enters $220 Million Finance Mandate to Fund Mexican Project Development
Vizsla Silver Enters $220 Million Finance Mandate to Fund Mexican Project Development
Sep 5, 2025
05:59 AM EDT, 09/05/2025 (MT Newswires) -- Vizsla Silver ( VZLA ) said Friday it secured a commitment of up to $220 million to fund the construction and development of the underground Panuco silver-gold project in Sinaloa, Mexico. A syndicate of banks will arrange the facility, with Macquarie Bank retaining a 70% interest and managing syndication of the remaining 30%,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved